Oral deucrictibant speeds symptom relief in HAE attacks, trial finds

RAPIDe-3, a phase 3 double-blind crossover trial, evaluated oral deucrictibant, a bradykinin B2 receptor antagonist, as on-demand treatment for hereditary angioedema attacks in participants aged 12 and older. The trial reported faster times to symptom relief with deucrictibant than placebo, with fatigue the only adverse event reported more than once shortly after treatment and no treatment-related serious or severe adverse events. The authors state these results support deucrictibant as a potential first orally administered B2 receptor antagonist for bradykinin-mediated angioedema attacks.

Most relevant for: Adolescents and adults with hereditary angioedema experiencing acute attacks who require on-demand treatment.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.